MDA 2020 virtual session: Duchenne muscular dystrophy (DMD): Examining the totality of evidence for corticosteroid treatment
Real-world and clinical study data examining corticosteroid treatment for DMD are presented in our session at the MDA 2020 Virtual Industry Forum
Review the role of inflammation in the pathophysiology of DMD
Real-world data for corticosteroid treatment of patients with DMD are presented
View the loss of ambulation outcomes in the Cooperative International Neuromuscular Research Group Duchenne Natural History Study (CINRG DNHS)
This virtual symposium took place at MDA 2020, and was sponsored by PTC Therapeutics Inc. The Forum is not an official event of the 2020 MDA Clinical and Scientific Conference and was not sponsored, endorsed, or accredited by MDA.
This virtual symposium recording has been chapterized to enable ease of viewing.
Deflazacort is a corticosteroid indicated for the treatment of Duchenne muscular dystrophy (DMD) in patients 2 years of age and older. PTC Therapeutics is the Marketing Authorization Holder for deflazacort in the US only. Registration conditions differ internationally, and prescribing information may vary depending on local approval in each country. The US Prescribing Information for deflazacort is available here. Please refer to your local country guidance for more information.
For medical information, product complaints, or to report an adverse event, please call 1-866-562-4620 or email at email@example.com. You may also report adverse events directly to FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.
Register now to unlock the content
Register now to access the content on this page
If not, register below
GL-DMD-0313 | June 2021
Sign in or register to access exclusive content on this site